• Je něco špatně v tomto záznamu ?

Snižování koncentrací lipidů tyreoidálními hormony a tyreomimetiky
[Lipid lowering with thyroid hormone and thyromimetics]

Bo Angelin, Mats Rudling

Jazyk čeština Země Česko

Typ dokumentu přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc11011708

To summarize how thyroid hormones exert their effects on lipid metabolism through specific interaction with their nuclear receptors, to review studies of the effects of new and selective thyromimetic drugs in animals and humans and to identify important questions for future research. RECENT FINDINGS: Thyroid hormones exert their effects by stimulation of thyroid hormone receptors that have different tissue distribution and metabolic targets. TRß is predominant in liver and mainly responsible for effects on cholesterol and lipoprotein metabolism, whereas TR? is most important in fat, muscle, and heart. Thyroid hormone analogs (thyromimetics, tiromes) have been developed that activate TRß and are selectively taken up and/or activated by the liver. Such compounds stimulate hepatic LDL receptors, cholesterol elimination as bile acids and cholesterol, and presumably promote reverse cholesterol transport. In animals, they retard atherosclerosis progression. In humans, eprotirome exerts favorable lipid-modulating effects while lacking thyroid hormone-related side-effects and maintaining normal hypothalamic-pituitary-thyroid feedback. When added to statins, it reduces LDL and non-HDL cholesterol, apolipoprotein B, and triglycerides as well as lipoprotein (a). SUMMARY: Liver-specific and ß-selective thyroid hormone analogs activate a spectrum of favorable thyroid hormone actions that optimize lipid metabolism and promote cholesterol elimination. Further studies should establish long-term safety and potential clinical usefulness of thyromimetics.

Lipid lowering with thyroid hormone and thyromimetics

Bibliografie atd.

Lit.: 49

000      
00000naa 2200000 a 4500
001      
bmc11011708
003      
CZ-PrNML
005      
20111210211101.0
008      
110525s2011 xr e cze||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a cze $b eng
044    __
$a xr
100    1_
$a Angelin, Bo $7 gn_A_00006888
245    10
$a Snižování koncentrací lipidů tyreoidálními hormony a tyreomimetiky / $c Bo Angelin, Mats Rudling
246    11
$a Lipid lowering with thyroid hormone and thyromimetics
314    __
$a Metabolism Unit, Department of Endocrinology, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden. bo.angelin@ki.se
504    __
$a Lit.: 49
520    9_
$a To summarize how thyroid hormones exert their effects on lipid metabolism through specific interaction with their nuclear receptors, to review studies of the effects of new and selective thyromimetic drugs in animals and humans and to identify important questions for future research. RECENT FINDINGS: Thyroid hormones exert their effects by stimulation of thyroid hormone receptors that have different tissue distribution and metabolic targets. TRß is predominant in liver and mainly responsible for effects on cholesterol and lipoprotein metabolism, whereas TR? is most important in fat, muscle, and heart. Thyroid hormone analogs (thyromimetics, tiromes) have been developed that activate TRß and are selectively taken up and/or activated by the liver. Such compounds stimulate hepatic LDL receptors, cholesterol elimination as bile acids and cholesterol, and presumably promote reverse cholesterol transport. In animals, they retard atherosclerosis progression. In humans, eprotirome exerts favorable lipid-modulating effects while lacking thyroid hormone-related side-effects and maintaining normal hypothalamic-pituitary-thyroid feedback. When added to statins, it reduces LDL and non-HDL cholesterol, apolipoprotein B, and triglycerides as well as lipoprotein (a). SUMMARY: Liver-specific and ß-selective thyroid hormone analogs activate a spectrum of favorable thyroid hormone actions that optimize lipid metabolism and promote cholesterol elimination. Further studies should establish long-term safety and potential clinical usefulness of thyromimetics.
650    _2
$a financování organizované $7 D005381
650    _2
$a zvířata $7 D000818
650    _2
$a ateroskleróza $x patofyziologie $x prevence a kontrola $7 D050197
650    _2
$a žlučové kyseliny a soli $x metabolismus $7 D001647
650    _2
$a biomimetika $x metody $7 D032701
650    _2
$a LDL-cholesterol $x metabolismus $7 D008078
650    _2
$a lidé $7 D006801
650    _2
$a statiny $x farmakologie $7 D019161
650    _2
$a systém hypotalamus-hypofýza $x fyziologie $7 D007030
650    _2
$a metabolismus lipidů $x účinky léků $7 D050356
650    _2
$a molekulární mimikry $x fyziologie $7 D018716
650    _2
$a orgánová specificita $7 D009928
650    _2
$a LDL-receptory $x agonisté $x metabolismus $7 D011973
650    _2
$a štítná žláza $x fyziologie $7 D013961
650    _2
$a tyreoidální hormony, receptory alfa $x agonisté $x metabolismus $7 D037021
650    _2
$a tyreoidální hormony, receptory beta $x agonisté $x metabolismus $7 D037042
650    _2
$a hormony štítné žlázy $x aplikace a dávkování $x chemická syntéza $x metabolismus $x terapeutické užití $7 D013963
655    _2
$a přehledy $7 D016454
700    1_
$a Rudling, Mats
773    0_
$w MED00156015 $t Current opinion in lipidology $g Roč. 5, č. 1 (2011), s. 16-22 $x 1802-372X
910    __
$a ABA008 $b B 2483 $c 129 $y 2
990    __
$a 20110525121334 $b ABA008
991    __
$a 20110725105503 $b ABA008
999    __
$a ok $b bmc $g 852832 $s 717797
BAS    __
$a 3
BMC    __
$a 2011 $b 5 $c 1 $d 16-22 $m Current Opinion in Lipidology $x MED00156015
LZP    __
$a 2011-08/mkme

Najít záznam